Project Grant R01HL179084
- This $775,992 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells and glucocorticoids in the resolution of acute lung injury and acute respiratory distress syndrome (ARDS). The research aims to determine how glucocorticoid signaling through regulatory T cells impacts the recovery of lung structure and function following...
- This federal Project Grant award, titled "RESILIENCE ENDOTYPE-DERIVATION THROUGH PARSIMONIOUS ANALYSIS AND CAUSAL INFERENCE OF RECOVERY FROM ACUTE RESPIRATORY DISTRESS SYNDROME (REPAIR-ARDS)", is funded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) in the amount of $674,351. The project aims to develop predictive models for early diagnosis of Acute Respiratory Distress Syndrome (ARDS) using protein biomarkers and clinical data, as...
- This $761,615 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of biological sex in the heterogeneity of Acute Respiratory Distress Syndrome (ARDS). The research team at Massachusetts General Hospital aims to determine how increased alveolar epithelial expression of Secretory Leukocyte Protease Inhibitor (SLPI) in females may increase epithelial glycocalyx resilience, leading to a...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance precision medicine for Acute Respiratory Distress Syndrome (ARDS) and sepsis. The $2,295,984 award to the University of California, San Francisco (UCSF) will fund research to address critical unanswered questions about the distinct molecular phenotypes of ARDS and sepsis, and how to optimize real-time phenotyping and integrate analyses of phenotype-specific...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $516,250.00 to Florida International University to develop novel RhoA nitration inhibitory peptides for the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The research aims to shield RhoA, a key protein, from nitration to protect endothelial barrier function, preserve mitochondrial function, and reduce inflammation during...
- This $480,990 Project Grant awarded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) aims to establish the central role of a recently identified lung cell type, "aerocytes," in regulating alveolar regeneration following lung injury. The research proposal has two key objectives: Investigate the role of aerocyte-derived R-spondin3 in lung growth and recovery using animal studies within disease-related lung injury models....
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a 2-year $189,000 research project led by an Assistant Professor at the University of Colorado to investigate the role of aldehyde dehydrogenase 2 (ALDH2) in the pathogenesis and resolution of fibroproliferative acute respiratory distress syndrome (FP-ARDS). The research aims to improve understanding of the mechanisms underlying pathologic pulmonary fibrogenesis...
- This federal Project Grant award of $200,502 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project led by Dr. Narges Alipanah-Lechner at the University of California, San Francisco (UCSF). The project aims to identify metabolite and protein drivers of the evolution of Acute Respiratory Distress Syndrome (ARDS) subtypes, specifically the hyper-inflammatory and hypo-inflammatory forms. The research will utilize comprehensive...
- This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, is focused on studying the role of indole metabolites as danger signals in the pathogenesis of acute respiratory distress syndrome (ARDS). The $688,163 award to the University of Pittsburgh covers the period from Sep 1, 2025 to May 31, 2029. The research aims to investigate how microbial-derived indole metabolites activate regulated cell death...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $791,503 to Weill Medical College of Cornell University to conduct research on the role of the thrombin receptor protease activated receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome (ARDS). The 4-year award, effective September 15, 2025, aims to investigate a previously unappreciated function of PAR1 in the lung lymphatic vasculature and its potential as a novel therapeutic target for ARDS, a devastating disease with high mortality. The research will use mouse models to study how PAR1 regulates lymphatic endothelial cell junctions and impacts fluid drainage and immune cell trafficking, key factors in the inflammatory response during lung injury. The findings could lead to new strategies for preventing and treating ARDS, an urgent need highlighted by the COVID-19 pandemic and other respiratory illnesses.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $791.5k | 9/9/25 |